C.R. Bard Inc.’s PowerPort series was once hailed as a breakthrough in the treatment of chronic illnesses that require repeated access to the vascular system. After receiving FDA approval in 2000, the devices quickly dominated the port-a-cath market and, by 2021, earned Bard nearly 70% market share.  However, PowerPort devices are prone to various complications […]

The post Attorneys Forecast Thousands of Bard PowerPort Lawsuits  appeared first on Dolman Law Group.